GLP-1s and breastfeeding: what the evidence shows

The answer depends on the medicine and its form

Breastfeeding deserves a more useful answer than a blanket yes or no. Small human studies now offer some information about injected semaglutide and tirzepatide in milk. They do not establish long-term safety for babies or effects on milk supply. Wegovy tablets have different advice because of their absorption ingredient, SNAC^1,3,4.

This guide checks the U.S. labels and published research as of October 22, 2026. Bring the exact product name and formulation to your prescriber and your baby's clinician. A plan needs to account for your health as well as your baby's feeding and growth.

Wegovy and Ozempic injections: label wording and published evidence

The Wegovy injection and Ozempic labels still report no human milk, infant-effect or milk-production data. Both ask clinicians to consider the benefits of breastfeeding, the mother's clinical need and possible effects from treatment or the underlying condition^1,2. That wording does not mean no research has been published outside the labels.

In a 2024 study, eight women provided milk while using injected semaglutide. Samples collected at 0, 12 and 24 hours relative to an injection had no detectable semaglutide. Weekly doses in the study ranged from 0.25 to 1 mg; these are study details, not a breastfeeding dose recommendation³.

The infant observations were short and reported by mothers, rather than a controlled infant-safety trial. Mothers described expected development and growth overall. One reported transient diarrhea and reduced appetite in her baby while she also had gastrointestinal symptoms; she reported that the child's growth curve remained unaffected. The study could not determine whether semaglutide caused those symptoms³.

The participants were beyond the early newborn period. The study did not establish safety for premature babies, exclusive breastfeeding, higher doses or long-term exposure. Milk production and composition were not measured, and sampling during early dose increases did not describe every stage of ongoing treatment. Undetectable means below the test's detection limit, rather than proof of absolutely no drug³.

Why Wegovy tablets have different advice

Wegovy's oral label describes a lactation study with semaglutide below the quantification limit in milk, but SNAC and/or its metabolites present. SNAC helps the tablet's semaglutide get absorbed. The label warns that infants may clear SNAC less efficiently and that accumulation could pose an unknown risk of serious adverse reactions. It therefore advises against breastfeeding during Wegovy tablet treatment¹.

The injected formulation does not contain SNAC. This difference does not make switching formulations a decision to make yourself. Nor can the injection study establish safety for compounded drops, lozenges or other oral products. Our guide to compounded oral and sublingual semaglutide claims explains why evidence for one formulation cannot simply be carried over to another.

Zepbound and Mounjaro: what the milk percentage means

Both tirzepatide labels describe a study of 11 healthy lactating women given one 5 mg injection. Tirzepatide was undetectable in 164 of 171 milk samples. The cumulative amount found in milk over 28 days was less than 0.02% of the administered maternal dose. These matching label descriptions should not be counted as two separate studies^4,5.

That percentage compares the amount recovered in milk with the mother's dose. It is not a measured drug level in a baby or a weight-adjusted relative infant dose. A single injection also cannot describe exposure during repeated weekly treatment. Both labels still report no data on infant effects or milk production^4,5. Low transfer is useful information for a clinician's assessment; it does not settle the whole safety question.

What to discuss before making a change

Ask your care team to work through these questions with you:

• What needs treatment now? Bring your diagnoses, current medicines and blood-sugar history. If you had gestational diabetes, our guide to care after gestational diabetes can help you organize that history.
• What does feeding look like? Explain your baby's age, whether they were premature, how much they rely on breast milk and any feeding or growth concerns.
• How are you eating and feeling? Discuss appetite, nausea, hydration and any existing supply concerns. The semaglutide study did not measure milk volume or nutrient composition³.
• What follow-up would be needed? Ask who will monitor your health, your baby's feeding and growth, and which symptoms should prompt a call.
• Could another pregnancy be possible? Pregnancy evidence and planning conception involve separate questions from breastfeeding. If tirzepatide is being considered, also discuss the label's oral-contraceptive precautions^4,5.

If you are already using a GLP-1

Contact your prescriber and your baby's clinician with the product, formulation, recent treatment history and feeding details. An exposure does not prove that harm has occurred. These small studies also cannot provide a reliable do-it-yourself waiting interval or pumping-and-discarding schedule.

Ask for an individual medication and feeding plan before starting, stopping or switching treatment. You do not need to decide to wean from this article. If treatment is being considered for later, the beginner's walkthrough explains the general assessment process; it does not establish eligibility while breastfeeding.